Jurox Pty Ltd, an Australian-based veterinary pharmaceutical company, is expanding to North America and has selected Kansas City, Missouri
, as its U.S. headquarters. The company’s expansion to Missouri will include a $741,000 capital investment and is expected to create 13 new, full time jobs.
“Kansas City is the obvious best location to launch Jurox’s U.S. operations,” said Jurox Managing Director John O’Brien. “Missouri offers a broad portfolio of animal health companies, a first-rate talent pool, and a superior transportation network that connects us to clientele around the country and globe. Kansas City’s reputation and resources in animal sciences provides advantages you can’t find elsewhere.”
Jurox is an established family owned veterinary pharmaceutical company that manufactures and markets in excess of 120 proprietary animal health products in over 20 countries. With global headquarters
in the Hunter Valley Australia, Jurox maintains commercial operations in New Zealand, United Kingdom. Looking to expand to North America, the company will establish its U.S. headquarters in Kansas City and will also locate several regional offices throughout the country.
“The Show-Me State has a rich history in the animal sciences sector and I’m proud to add to that legacy today by welcoming Jurox to Kansas City,” said Governor Jay Nixon
. “Jurox’s decision to locate its U.S. headquarters right here in Missouri further validates that there’s no better place to do business than the Show-Me State. With our trained workforce
and low business-costs, Missouri makes it easy for companies to invest and hire.”
"I’m thrilled that Jurox, an animal health company with an international profile, will be putting down roots in Kansas City,” said Mayor Sly James. “This announcement is further proof that our economy is growing in all the right ways and with an eye towards high growth industries of the future."
To assist Jurox with its expansion, the Missouri Department of Economic Development
has offered a strategic incentive package
that the company can receive if it meets strict job creation and investment criteria.